The Pilbara Minerals Ltd (ASX: PLS) share price has suffered through plenty of volatility in 2022 so far, but the stock could be set to outperform over the coming 12 months.

The S&P/ASX 200 Index (ASX: XJO) lithium stock reached a high of $3.89 in January before hitting a low of $1.975 in June, marking a 49% tumble between its year-to-date high and low.

Fortunately, it has since recovered most of its losses. The Pilbara Minerals share price is trading at $3.66 right now. That’s 4% higher than it was at the start of this year.  

For context, the ASX 200 has dumped 8% year to date.

And there are plenty more signs pointing to the company being a financial year 2023 winner.

Keep reading to find out what might be in store for the company and why some experts are bullish on its stock.

Could the Pilbara Minerals share price take off in FY23?

Could financial year 2023 (FY23) be the year in which the Pilbara Minerals share price takes off once again? Well, we can’t predict the future, but there are plenty of signs the company could outperform over the near term.

For one, it just reported its maiden profit, bringing in a net profit after tax (NPAT) of $561.8 million for FY22. And it has big expectations for the future.

It believes it will up its production of spodumene concentrate to between 540,000 and 580,000 dry metric tonnes in FY23 – marking a potential 53% year-on-year increase.

However, it also expects its unit operating costs to lift from $555 per dry metric tonne to between $635 and $700 per dry metric tonne.

To top it off, the company believes the lithium deficit could surge to around 1.8 million tonnes by 2040 on a base case basis, likely causing the material’s value to soar.

The company’s not alone in expecting big things from lithium prices. Broker Macquarie believes rising lithium prices will drive the Pilbara Minerals share price higher over the next year.

It has slapped the stock with a $5.60 price target, implying a 54.3% upside, as my Fool colleague Tristan reports.  

However, Credit Suisse is reportedly wary that the company’s costs could surge.

It’s placed a $2.30 price target on Pilbara Minerals shares, representing a potential 36.6% downside.

The post Could the Pilbara Minerals share price really offer more than 50% upside in FY23? appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Could this new piece of legislation be a boost for ASX lithium shares?
• Here are the 3 most heavily traded ASX 200 shares on Tuesday
• Why is the Novonix share price tumbling 6% on Monday?
• Here are the 3 most heavily traded ASX 200 shares on Monday
• Are Pilbara Minerals shares better value than Allkem right now?

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/njyNfA1

The Imugene Limited (ASX: IMU) share price is on mute after the ASX-listed biotech company reported its results for FY22.

After a wobbly start this morning, the Imugene share price has now stalled at yesterday’s closing price of 24 cents despite a significant jump in the company’s net loss for FY22.

Imugene is a clinical-stage immuno-oncology company developing new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours.

Let’s take a look at the Imugene results for FY22.

What did Imugene report for FY22?

As mentioned, Imugene is still at a clinical stage, so it’s yet to produce any revenue. Imugene currently receives income from Australian government incentives, which increased from $7.2 million in FY21 to $12.6 million in FY22.

Research and development (R&D) expenses more than doubled from $15.4 million in FY21 to $36.6 million in FY22. General and administrative expenses also lifted, from $10.3 million in FY21 to $14 million in FY22.

Overall, Imugene recorded a net loss of $37.9 million in FY22 compared to a net loss of $18.5 million in FY21.

The current cash balance stands at $99.9 million, so there is ample capital for Imugene to continue with its clinical trials.

What else happened in FY22?

Earlier this month, Imugene provided a positive update as the first patient from the third cohort of the Checkvacc Phase 1 clinical trial had been dosed. The Imugene share price shot up 11% on this news.

Since the update, Checkvacc has progressed to dosing for cohort 3 in triple-negative breast cancer patients. Management plans to disclose the results of these studies later.

Imugene also completed phase 2 in HER-2/Neu overexpressing advanced gastric cancer.

The biotech company also presented new PD1-Vaxx data from non-small cell lung cancer patients at the IASLC 2022 World Conference on Lung Cancer in Vienna, Austria. This data shows early positive signs as the company progresses towards a phase 1b combination study.

What did management say?

Commenting on the FY22 results, Imugene executive chair Paul Hopper said:

As our deep pipeline has continued to advance and strengthen, it provides a wide range of possibilities and opportunities for Imugene moving forward. Financially, the company remains in an enviable position with a long cash runway that allows us to continue our clinical programs unimpeded.

This was reinforced by the $90 million placement conducted early in the financial year alongside a further $5 million raise via a Share Purchase Plan. Both received overwhelming support and we thank those investors that participated.

It appears management is confident in its current financial position, and now it’s a matter of delivering the results. Patience is required in these types of businesses because it could take years for a commercial solution to develop.

What’s next for Imugene?

The plan is for PD1-Vaxx to be tested in combination with atezolizumab (Tecentriq) in patients with non-small cell lung cancer. Imugene locked in a second clinical supply agreement with Roche. The testing will be completed at sites in Australia and the United States.

As for Imugene’s latest technology onCARlytics, the company advised of collaborations with two US-based partners, Celularity and Eureka Therapeutics. This partnership involves investigating the combination of Imugene’s CD19 oncolytic virus technology with T cell therapies being developed by each partner.

Imugene share price snapshot

The Imugene share price has suffered a big fall of 43% in the last 12 months but is looking to make amends with a 4% jump over the last month. The S&P/ASX 200 Index (ASX: XJO) has fallen 7% in the past year and is down 0.3% in the past month.

Imugene has a market capitalisation of around $1.4 billion.

The post Net loss doubles in FY22, so what’s with the Imugene share price today? appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Here are the top 10 ASX 200 shares today
• The Imugene share price has tumbled 18% since the company’s last update. What’s happening?
• Here are the top 10 ASX 200 shares today
• Here are the 3 most heavily traded ASX 200 shares on Wednesday
• Why Graincorp, Imugene, iSelect, and Mayne Pharma shares are racing higher

Motley Fool contributor Raymond Jang has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/zDbkYEG

The 4DMedical Ltd (ASX: 4DX) share price is trading 23% into the green on Wednesday following a company update.

Investors are rallying the share after it announced a “major success” in the ‘burn pit’ clinical trial. The trial is being conducted by Vanderbilt University Medical Centre, in Nashville in the United States.

What did 4DMedical announce?

Preliminary results indicate that 4DMedical’s XV Technology can detect constrictive bronchiolitis in military veterans, where pulmonary function tests (PFTs) and CT scans have failed to do so.

The XV Technology is a medical imaging platform that uses image-processing methods taken from aerospace engineering to perform deeper respiratory analysis.

Curiously, the background for the trial stems from a pattern of “disabling” respiratory symptoms observed in US military personnel. The symptoms include shortness of breath and coughing, but are severe enough to significantly impact daily function.

It is understood that exposure to toxic chemical fumes when disposing of and burning hazardous/non-hazardous waste was a factor for the personnel during their time serving in the Middle East.

The U.S. military constructed burn pits near bases across the Middle East to dispose of hazardous
and non-hazardous waste.

A wide range of materials, including uniforms, chemicals, tyres, and even medical, animal and human waste, were burned in pits using jet fuel as an accelerant.

It is estimated that 3.5 million Veterans have been exposed to harmful toxins whilst deployed on operations since 2001.

The ‘burn pit’ trial looked at this symptomology and showed that XV Technology is accurate in identifying the constrictive bronchitis.

4DMedical also advised that it has a pre-agreed pricing structure with the Veteran Health Association (VHA). The agreement means the company can offer the procedure at US$171 per scan – without the need for reimbursement.

In the last 12 months, the 4DMedical share price is down more than 61%.

The post Why is the 4DMedical share price rocketing 20% on Wednesday? appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Why has the 4D Medical share price popped 7% in a month?

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/WsF1IRh

The Best & Less Group Holdings Ltd (ASX: BST) share price is plummeting in midday trade, currently down 15%.

Shares of the iconic clothing retailer are currently trading for $2.295 each after closing on Tuesday at $2.70 a share.

By comparison, the S&P/ASX 200 Index (ASX: XJO) is down 0.32% while the S&P/ASX 200 Consumer Discretionary Index (ASX: XDJ), which Best & Less is a part of, is down just 0.14% at the time of writing

It seems Best & Less’s steep selloff isn’t in step with major market movements. So what’s going on? Let’s investigate.

What’s going on with the Best & Less share price?

There’s no news out of Best & Less today to help make sense of the company’s share price movement.

But yesterday, the retailer posted mixed results in its financial report for FY22. After enjoying an early rally on the back of its results, the company’s shares closed 3% higher on the day.

In its results, Best & Less noted considerable headwinds from COVID-19 that challenged the report’s top and bottom lines.

Both revenue and earnings before interest, taxes, depreciation and amortisation (EBITDA) shrank during the period. Revenue finished at $622 million, down 6.2% year over year, while EBITDA finished at $62.5 million, down 12.7% year over year.

The company announced a final dividend of 12 cents per share. It prompted my colleague Bruce Jackson to mention Best & Less in a roundup post yesterday, noting that the company’s dividend yield of 3.91% was “attractive”.

The company also provided an optimistic update on FY23 so far, reporting total sales were up 38% over the prior corresponding period in the first eight weeks of trading.

But it seems investors are reconsidering the company’s position today.

Best & Less share price snapshot

The Best & Less share price is currently down 44% year to date. Meanwhile, the S&P/ASX 200 Index (ASX: XJO) is down around 8% over the same period.

The company’s market capitalisation is roughly $287 million.

The post Why is the Best & Less share price crashing 15% on Wednesday? appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• ASX dividend windfall continues but it’s not just Woodside and ASX 200 energy stocks splashing the big cash
• Best & Less share price surges 7% on sharp FY22 results

Motley Fool contributor Matthew Farley has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/c8DaGL4

Australian markets are off to a poor start on Wednesday, with the S&P/All Ordinaries Index (ASX: XAO) down 32 basis points to 7,207 at the time of writing.

Meanwhile, the DGL Group Ltd (ASX: DGL) share price has faltered more than 23% in trade this Wednesday following the release of its FY22 results.

DGL Group shares slide in first year of listing

Key takeouts from the All Ords share’s results include:

• Sales revenue of $369.8 million, up 88% on pro-forma FY21 revenue and up 4% on guidance
• Underlying EBITDA of $65.6 million, a gain of 133% on pro-forma FY21, and 1% above prospectus guidance
• Underlying earnings before interest and tax (EBIT) of $48.4 million an increase of 188% on pro-forma FY21 results
• Underlying net profit after tax (NPAT) of $33.6 million, up 197% on pro-forma FY21 profit
• $25.4 million in cash on the balance sheet with $66 million in net bank debt
• Nil dividends paid

What else happened last period for DGL Group?

Growth was observed across all operating segments and throughout the income statement for FY22.

This included chemical manufacturing, warehousing and distribution and environmental solutions, up 141%, 54% and 39% year on year respectively.

Performance was underlined by higher demand for DGL’s services, higher selling prices, and sales revenue contributions from acquired businesses.

In addition, and “following inappropriate public comments expressed by a senior company representative”, the board “engaged culture expert Rhonda Brighton-Hall and her firm MWAH to conduct the independent review”.

“The review found DGL has a diverse workforce and a positive and inclusive culture that is both hard-working and ambitious. Trust and respect were found to be consistent across the business.”

Management commentary

Speaking on the performance, DGL Founder and CEO, Simon Henry said:

Building on our strong momentum in the first half of 2022, we have delivered exceptional results for the 2022 financial year with growth across all earnings metrics. This is a testament to our ability to grow sustainably by offering a fullservice solution for our customers, achieving further economies of scale, and identifying appropriate acquisitions.

All three of our operating divisions performed exceedingly well, benefitting from our deep customer relationships and robust demand as customers continue to onshore their chemical supply chain and hold onto more inventory.

Our deep supplier relationships, capabilities across the supply chain and robust balance sheet mean we are well positioned for another successful year in FY23.

What’s next for DGL Group?

DGL noted many uncertainties in its operations and operating environment looking ahead. With that in mind, it did not provide further guidance for FY23.

Instead, the All Ords share will provide a trading update at its annual general meeting.

The post Why did this ASX All Ords share just crater 23%? appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Expert names 2 ASX shares to buy for ‘extended, uninterrupted’ good times

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended DGL Group Limited. The Motley Fool Australia has recommended DGL Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/JPdqoLa

The Atlas Arteria Group (ASX: ALX) share price is on the move today after the ASX 200 toll road group handed in its first-half 1H22 results.

While the S&P/ASX 200 Index (ASX: XJO) reverses by 0.4% in late morning trade, the Atlas Arteria share price has climbed 0.9% to $8.04.

Atlas Arteria share price rallies as COVID recovery continues 

Here’s a summary of the headline results from Atlas’ first-half report:

• Weighted average traffic was 22.7% above 1H21 and just 1.3% below 1H19
• Toll revenue came in at $53.8 million, up 25% on the prior corresponding period (pcp) of 1H21
• APRR toll revenue grew by 20% on the pcp to €1,290 million
• Statutory net profit after tax (NPAT) soared 184% on the pcp to $117.1 million
• Distribution guidance of 20 cents for 1H22 and a further 20 cents for 2H22

A record full-year distribution of 40 cents would represent an 11% increase over FY21. It puts Atlas shares on a prospective forward dividend yield of 5%.

However, for now, this is simply guidance. Atlas expects to announce its first-half distribution in September. 

On the whole, Atlas’ first-half growth was driven by increased traffic across the APRR network and the easing of COVID restrictions.

APRR is the second-largest toll road network in France and the fourth-largest motorway group in Europe. 

Atlas holds a 31.14% indirect interest in APRR, which brings in the lion’s share of the group’s revenue. In the first half, APRR contributed to 90% of Atlas Arteria’s revenue.

What else happened in 1H22?

APRR traffic was the highlight, increasing by 23.4% on the pcp on the back of a busy winter holiday period, strong domestic tourism, and reduced COVID restrictions across Europe. Notably, these traffic levels were 2.3% higher than pre-COVID levels of 1H19.

During the half, APPR expanded its network with the addition of the A79 motorway in southern France. Construction of the 88km road upgrade is expected to finish in late 2022, with tolling to commence on opening.

The roll-out of electric vehicle charging stations across the APRR network continues. Around 70% of motorway service areas are now equipped with high or very high power terminals. 

At Dulles Greenway in the United States, Atlas’ second-largest contributor of revenue, traffic increased by 12.3% on the pcp. However, traffic remained 34% lower than 1H19 due to the delayed return to office-based work.

What did management say?

Commenting on the results, Atlas Arteria CEO Graeme Bevans said:

Atlas Arteria delivered a strong result during the period, driven by improved operating conditions across France, Germany and the USA.

Atlas Arteria is well positioned in the current high inflationary environment. In 2022 we are absorbing some inflationary impacts in our costs given higher pricing, however with toll prices at APRR, ADELAC and Warnow Tunnel directly linked to inflation and a high proportion of fixed debt across the portfolio, securityholders stand to benefit from 2023 onwards.

What’s next?

Commenting on the outlook, Atlas noted that its financial performance was positively correlated to inflation. Thus, shareholders stand to benefit during a high inflationary environment.

This is because most of the toll prices across Atlas’ network are directly linked to inflation. In other words, it can hike up toll prices as inflation soars.

Rounding out its outlook statement, Atlas believes it has strong organic growth potential within the current portfolio and continues to focus on improving average concession life.

Atlas Arteria share price snapshot

Since Atlas benefits from rising inflation, the Atlas Arteria share price has bucked the broader ASX 200 this year to punch in strong gains.

In the last six months, the Atlas Arteria share price has jumped 24%. Zooming out further, Atlas shares are up 17% in the last year.

The post Atlas Arteria share price drives higher on record dividend guidance appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Here are the top 10 ASX 200 shares today
• Up 4% today, could this ASX 200 share finally receive a takeover bid?

Motley Fool contributor Cathryn Goh has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/Lw1x97p

The Harvey Norman Holdings Limited (ASX: HVN) share price is in the red after the company posted its earnings for financial year 2022.

Shares in the S&P/ASX 200 Index (ASX: XJO) electronics and homewares retailer opened at $4.33 each this morning and slipped to an intraday low of $4.23 a share.

At the time of writing, the Harvey Norman share price is $4.24, 2.08% lower than its previous close.

Harvey Norman share price falls on FY22 earnings

Here are the key takeaways from the ASX 200 giant’s full-year results:

• Sales came to $9.5 billion – a 1.7% fall on that of the prior corresponding period (pcp)
• Profit after tax slipped 3.6% to $811.5 million
• Earnings before interest, tax, depreciation, and amortisation (EBITDA) slumped 1.4% to $1.4 billion
• Basic earnings per share (EPS) came to 65.13 cents
• Declared a 17.5 cent fully franked final dividend, bringing its full-year payout to 37.5 cents – a 7.1% improvement on that of FY21

Harvey Norman revealed 25% of its pre-tax profits, excluding property revaluations, last financial year came from its overseas retail stores.

In Australia, its franchisees were impacted by COVID-19-induced lockdowns in the first half. The segment’s pre-tax profit fell 12% year on year to $628.19 million despite it posting a record second half.

The company’s property segment closed the period with assets exceeding $3.7 billion and a $366.5 million pre-tax profit – a 25.7% improvement.

What else happened in FY22?

The retailer opened three new Australian company-owned stores in FY22, located in Murwillumbah, Port Pirie, and Charters Towers. It also opened a new company store in Malaysia and a commercial outlet in New Zealand.

The Harvey Norman share price tumbled 32% over the 12 months to 30 June.

What did management say?

Harvey Norman chair Gerry Harvey commented on the company’s results, saying:

Our omni channel strategy continues to deliver, our balance sheet is strong, our cash reserves are solid and we continue to maintain a low net debt to equity ratio of 10.31%. With experienced management, we have grown our integrated retail, franchise, property, and digital business across eight countries to nearly $10 billion in system sales.

Cash conversion in FY22 has significantly improved compared to FY21 predominantly due to a $53.43 million increase in net cashflows from operating activities, from $543.87 million in FY21 to $597.30 million for FY22. The solid cash flows generated from operating activities this year will enable us to further enhance and promote our brand locally and overseas to grow our businesses, refurbish our existing stores and invest in new property acquisitions and pay down external debt.

What’s next?

The company didn’t provide any new earnings guidance today. However, it outlined a number of expectations for the current financial year and provided a trading update.

It plans to open two new franchised complexes in Australia and relocate another to a freehold property in FY23. Overseas, it opened its 16th company-operated store in Ireland in July and expects to ramp up its offshore expansion plans with four more company-operated stores in New Zealand, Malaysia, and Croatia.

The period from 1 July to 29 August saw its sales grow in all regions except Ireland and Northern Ireland. They saw respective decreases of 1% and 10.2% on those of the pcp.

Australian sales, meanwhile, lifted 10.7%, while those of Malaysia and Slovenia and Croatia rose 108% and 12.2% respectively.

Harvey Norman share price snapshot

The Harvey Norman share price has had a rough trot of late.

It has fallen 14% since the start of the year. It’s also currently 21% lower than it was this time last year.

For comparison, the ASX 200 has sunk 8% year to date and 7% over the last 12 months.

The post Harvey Norman share price slips despite FY22 sales nearing $10b appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• 5 things to watch on the ASX 200 on Wednesday
• Why are ASX 200 retail shares having such a stellar run today?
• 2 ASX 200 dividend shares with ~7%+ yields that experts rate as buys
• What’s impacting ASX 200 retail shares today?
• 2 ASX 200 dividend shares analysts rate as buys

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Harvey Norman Holdings Ltd. The Motley Fool Australia has positions in and has recommended Harvey Norman Holdings Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/CUX6zZA

The MoneyMe Ltd (ASX: MME) share price is on ice today following a company-requested trading halt on Tuesday.

Aside from this, the company also posted its FY22 full-year results before the open today as well.

The MoneyMe share price is resting at 69 cents, down more than 68% this year to date.

Why is the MoneyMe share price halted?

The company notes it requested the trading halt of its securities for a planned equity raise.

It is undertaking a fully underwritten placement to raise $20 million. To do this, it will issue 40 million new fully-paid ordinary shares.

MoneyMe will issue the placement shares at a fixed price of 50 cents apiece, representing a 28.1% discount to the last close price on Monday – just before the halt.

Specifically, it hopes to raise approximately $17.84 million through the issue of approximately 35.7 million shares in an unconditional offer.

Then, it wants to raise the additional $2.16 million through a conditional placement that will require shareholder approval.

“The proceeds from the equity raising will be utilised for equity subordination requirements in MoneyMe’s warehouse facilities to support continued loan book growth, and payment of associated upfront commissions to brokers,” the company said.

“In its normal course of business, MoneyMe will continue to explore opportunities to expand new and existing debt capital facilities to support its balance sheet and loan receivables growth,” it added.

The MoneyMe share price is expected to remain in a trading halt until Thursday, whilst the equity raise is being completed.

MoneyMe shares remain down more than 66% in the past 12 months of trade.

The post MoneyMe share price halted amid results and cap raise appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Why the Amazon share price slumped on Tuesday
• Here’s why analysts have slapped buy ratings on these ASX shares
• Praemium share price spikes hard as profit soars in FY22
• Why Bitcoin, Ethereum, and Dogecoin are falling today
• Webjet share price ascends 11% amid profitable start to FY23

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/Vgnt4A8

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

What happened

A broad cross section of stocks stumbled on Tuesday, as market watchers focused on deteriorating macroeconomic conditions and the potential that things could get worse before they get better.

E-commerce platform Amazon (NASDAQ: AMZN) stock was down as much as 2.3% on Tuesday morning, mobile games platform Skillz (NYSE: SKLZ) slipped as much as 5.1% and online used car retailer Carvana (NYSE: CVNA) was off by as much as 6.7%. As of 2:34 p.m. ET, the trio were still trading lower, down 1.5%, 2.9%, and 3%, respectively. These stocks followed the broader market lower, as the S&P 500 gave up 1.2%, while the Nasdaq Composite declined more than 1.4%.

There was very little in the way of company-specific news behind the sell-off, but fears regarding the faltering economy intensified as investors weighed the possibility that they could be facing higher inflation and the potential for a prolonged recession.

So what

A report released Tuesday by the Bureau of Labor Statistics added to the growing mountain of evidence that the economy could be worse off than originally expected. The Job Openings and Labor Turnover Summary for July found that there were almost 1 million more job openings than market watchers expected. The total number of available positions rose to 11.24 million, far exceeding the 10.3 million predicted.

Economists have been keeping a close eye on the growing shortage of candidates to fill the available positions, a situation that seems to be getting worse instead of better. There are now nearly two jobs openings for each available candidate. As a result, prospective employers are forced to offer higher wages in order to entice potential employees, which in turn increases inflationary pressures.

In another sign of the tightening job market, the number of job openings increased in July compared to June, with an additional 200,000 positions going unfilled.

The news come on the heels of remarks by Federal Reserve Bank chair Jerome Powell late last week that suggested the Fed would continue its aggressive campaign to combat inflation. “While higher interest rates, slower growth, and softer labor market conditions will bring down inflation, they will also bring some pain to households and businesses,” Powell said. “These are the unfortunate costs of reducing inflation.”

The Fed has been working to reduce the number of unfilled positions without sparking higher unemployment. Unfortunately, the red-hot job market increases the likelihood that the central bank will be forced into another 0.75% rate increase when policymakers meet again in September, which would mark the third successive rate hike of this magnitude in four months.

Now what

So what does this all have to do with this trio of companies? The continuing prospect of an economic slowdown will weigh on a great many consumer discretionary stocks.

The potential for even higher interest rates will likely result in “pain” for consumers, according to Powell. Indeed, the average household is already making difficult decisions caused by higher costs for food and fuel. If the faltering economy further reduces consumer spending, it’s conceivable that consumers will cut back on e-commerce purchases, forgo the purchase of a new car, or refuse to lay out hard-earned cash for competitive games of chance.

That said, for investors who are already sold on the prospects of Amazon, Carvana, and Skillz, the economic headwinds will eventually abate. That gives investors the opportunity to use temporary price slumps like these as an opportunity to get shares at a discount.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

The post Why the Amazon share price slumped on Tuesday appeared first on The Motley Fool Australia.

(function() { function setButtonColorDefaults(param, property, defaultValue) { if( !param || !param.includes(‘#’)) { var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0]; button.style[property] = defaultValue; } } setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’); setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’); setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’); })()

More reading

• Why Amazon’s latest green hydrogen partnership is a big deal
• 2 genius reasons to buy Amazon stock today
• Does this make Amazon stock a buy?
• Why Amazon stock was slipping today
• Better buy stock: Alphabet vs. Amazon

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Danny Vena has positions in Amazon and Carvana Co. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Amazon and Skillz Inc. The Motley Fool Australia has recommended Amazon. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

from The Motley Fool Australia https://ift.tt/BkzrM5I

With a new month approaching, what better time to look at making some new additions to your portfolio.

Two ASX shares that could be worth considering are listed below. Here’s what analysts are saying about them:

Lovisa Holdings Ltd (ASX: LOV)

The first ASX share to look at is fashion jewellery retailer Lovisa.

It could be a top option for investors due to its enormous long term growth potential thanks to its global expansion plans.

It is for this reason that the team at Morgans is so bullish on the company and has an add rating and $24.50 price target on its shares. The broker commented:

What was clear to us from LOV’s FY22 result was that this is a global growth story that is really only just getting started. FY22 earnings were certainly impressive, with sales beating our forecasts rising 59% and statutory EBIT before LTI more than double that of the prior year. Even the dividend, at 74c for the year, was a very positive surprise. But all this could be just a taste of things to come.

What was even more remarkable than the result itself was the phenomenal scale of LOV’s ambition. In its own words, LOV is ‘building a global brand’, which will involve the development of a global presence that we believe will far out scale the 651 stores in the portfolio today.

Objective Corporation Limited (ASX: OCL)

Another ASX share that could be in the buy zone is software company Objective Corp.

It recently released its full year results and delivered a 15% increase in annualised recurring revenue (ARR).

The team at Goldman Sachs expects this strong form to continue and is forecasting ARR growth of 18% in both FY 2023 and FY 2024.

As a result of this strong growth outlook, the broker has put a buy rating and $18.40 price target on its shares. Goldman commented:

Objective Corp is a leading provider of software solutions to the public sector in ANZ and the UK, with a growing presence in the US. Objective has a long history of organic product development and accretive M&A which has helped support growth as its core Enterprise Content Management (ECM) product matures.

We are attracted to management’s track record of growth and margin expansion and see upside being driven from 1) new products including Build and RegWorks; and 2) expansion in the US over time. When adjusting for OCL’s conservative accounting (100% of R&D expensed), robust growth outlook, defensive end markets and high franchise quality, we see valuation appeal compared to SaaS peers and believe the shares can outperform in a more challenging macro environment.

The post Here’s why analysts have slapped buy ratings on these ASX shares appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• 3 ASX All Ords shares tumbling lower following full-year results
• Why A2 Milk, Lovisa, McMillan Shakespeare, and Tyro are storming higher
• Lovisa share price lifts as full-year profit surges 116%
• Top brokers name 3 ASX shares to buy next week
• Goldman Sachs just slapped a buy rating on this ASX tech share

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Objective Corporation Limited. The Motley Fool Australia has recommended Lovisa Holdings Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/EsK7hz8